Image

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Study of Investigational Medication with mFOLFIRINOX for Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
18 years and older
All
Phase 1
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study investigates the use of an MK2 inhibitor in combination with mFOLFIRINOX for the treatment of metastatic pancreatic ductal adenocarcinoma.

The study evaluates the potential benefits of adding an MK2 inhibitor to the standard mFOLFIRINOX chemotherapy regimen. It seeks to understand how this combination might improve treatment outcomes for patients with this type of cancer.

  • Who can participate: Adults aged 18 and older with confirmed pancreatic ductal adenocarcinoma and measurable disease may participate.
  • Study details: Participants will receive an investigational medication along with mFOLFIRINOX chemotherapy. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
Print
Study details
    Metastatic Pancreatic Ductal Adenocarcinoma
    Pancreatic Cancer
    Cancer of the Pancreas

NCT06648434

Washington University School of Medicine

31 July 2026

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.